SEC Filing Summary: AspenBio Pharma, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AspenBio Pharma, Inc. on October 31, 2011, covering events occurring on October 28 and October 31, 2011. The registrant is incorporated in Colorado and operates in the pharmaceutical sector. Note: The request metadata referenced "Riot Platforms, Inc."; however, the provided filing text explicitly identifies the registrant as AspenBio Pharma, Inc.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses on corporate events rather than financial performance results.
Material Changes and Events
- Website Update: On October 28, 2011, the Company posted an update presentation on its website (filed as Exhibit 99.1).
- ISO Certification: On October 31, 2011, the Company announced it was awarded ISO 13485 Certification (filed as Exhibit 99.2).
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on financial outlook, or specific risk factors. The primary disclosure is the achievement of ISO 13485 certification, which indicates compliance with quality management systems for medical devices.
Investor Verification Checklist
- Verify the content of the "Company Update Presentation" (Exhibit 99.1) for strategic or operational details not summarized in the 8-K.
- Review the press release regarding ISO 13485 Certification (Exhibit 99.2) to understand the scope of the certification and its impact on product development or regulatory approval.
- Confirm the company's current financial status through the most recent 10-Q or 10-K filing, as this 8-K contains no financial figures.